Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry

(1)

HAL Id: inserm-00823374

https://www.hal.inserm.fr/inserm-00823374

Submitted on 16 May 2013

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci-entific research documents, whether they are pub-lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Correction: Disease and patient characteristics in NP-C

patients: findings from an international disease registry

Marc Patterson, Eugen Mengel, Frits Wijburg, Audrey Muller, Barbara

Schwierin, Harir Drevon, Marie Vanier, Mercé Pineda

To cite this version:

Marc Patterson, Eugen Mengel, Frits Wijburg, Audrey Muller, Barbara Schwierin, et al.. Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet Journal of Rare Diseases, BioMed Central, 2013, 8 (1), pp.73. �inserm-00823374�

(2)

C O R R E C T I O N

Open Access

Correction: Disease and patient characteristics in

NP-C patients: findings from an international

disease registry

Marc C Patterson1,8*, Eugen Mengel2, Frits A Wijburg3, Audrey Muller4, Barbara Schwierin4, Harir Drevon5, Marie T Vanier6and Mercé Pineda7

Correction

After the publication of this work [1] it was brought to the authors attention that Figure 1 contained an inver-sion in the color of the triangles, where yellow which should be "diagnosis" is said to be "first miglustat use", and blue which should be " first miglustat use" is said to be " diagnosis". The correct figure is given below:

Author details

1_{Mayo Clinic, Rochester, MN, USA.}2_{Villa Metabolica, ZKJM, MC, University of}

Mainz,, Mainz, Germany.3_{Academic Medical Centre, University of Amsterdam,}

Amsterdam, The Netherlands.4_{Actelion Pharmaceuticals Ltd, Allschwil,}

Switzerland.5_{Numerus Ltd, Wokingham, UK.}6_{INSERM Unit 820, Lyon, France.} 7_{Fundació Hospital Sant Joan de Déu, Barcelona, Spain.}8_{Department of}

Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Received: 7 May 2013 Accepted: 7 May 2013 Published: 14 May 2013

References:

1. Patterson MC, Eugen M, Wijburg FA, Audrey M, Barbara S, Harir D, Vanier MT, Mercé P: Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet Journal of Rare Diseases 2013, 8:12.

doi:10.1186/1750-1172-8-73

Cite this article as: Patterson et al.: Correction: Disease and patient characteristics in NP-C patients: findings from an international disease registry. Orphanet Journal of Rare Diseases 2013 8:73.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission

• Thorough peer review

• No space constraints or color figure charges

• Immediate publication on acceptance

• Inclusion in PubMed, CAS, Scopus and Google Scholar

• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

* Correspondence:patterson.marc@mayo.edu

1_{Mayo Clinic, Rochester, MN, USA}

8_{Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN}

55905, USA

Full list of author information is available at the end of the article

© 2013 Patterson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patterson et al. Orphanet Journal of Rare Diseases 2013, 8:73 http://www.ojrd.com/content/8/1/73

(3)

0 5 10 15 20 25 30 35 40 45 50 55 60 Age (Years)

Period before neurological manifestations Period with neurological manifestations Period on miglustat

First miglustat use (period on miglustat not specified) Diagnosis

Figure 1 Overview of patient and disease characteristics.We regret any inconvenience that this inaccuracy may have caused.

Patterson et al. Orphanet Journal of Rare Diseases 2013, 8:73 Page 2 of 2 http://www.ojrd.com/content/8/1/73